Cargando…

Refractory Cardiogenic Shock from Right Ventricular Infarction Successfully Managed with Inhaled Epoprostenol

Patient: Male, 53 Final Diagnosis: Cardiogenic shock from acute right colonary artery infarction Symptoms: Altered mental state Medication: — Clinical Procedure: Inhaled epoprostenol Specialty: Cardiology OBJECTIVE: Unusual clinical course BACKGROUND: Recognition and appropriate management of right...

Descripción completa

Detalles Bibliográficos
Autores principales: Held, Natalie, Little, Nathaniel, Krantz, Mori J., Stauffer, Brian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363174/
https://www.ncbi.nlm.nih.gov/pubmed/28298620
http://dx.doi.org/10.12659/AJCR.901975
Descripción
Sumario:Patient: Male, 53 Final Diagnosis: Cardiogenic shock from acute right colonary artery infarction Symptoms: Altered mental state Medication: — Clinical Procedure: Inhaled epoprostenol Specialty: Cardiology OBJECTIVE: Unusual clinical course BACKGROUND: Recognition and appropriate management of right ventricular (RV) infarction is essential, as RV injury increases mortality and substantially alters management during acute coronary syndrome. We report a case of RV infarction presenting with new right bundle branch block (RBBB), and therapeutic use of inhaled epoprostenol to reduce RV afterload and augment cardiac output during refractory cardiogenic shock. CASE REPORT: A 53-year-old male presented to our institution in ventricular fibrillation with subsequent development of RBBB in the setting of proximal right coronary artery occlusion. Following percutaneous coronary intervention, the patient developed severe RV dysfunction with refractory cardiogenic shock. This was successfully managed with inhaled epoprostenol with normalization of right ventricular systolic function. CONCLUSIONS: Although typically associated with anterior myocardial infarction, new RBBB should be recognized as a potential presenting sign of acute RV infarction. The use of inhaled epoprostenol in the setting of RV infarction has not been previously described, but it may augment right ventricular cardiac output via pulmonary vasodilatation.